Pages that link to "Q83629811"

The following pages link to HER2 expression and its clinicopathological features in resectable gastric cancer (Q83629811):

Displaying 41 items.

• Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients (Q21261244) (← links)
• Gastric biomarkers: a global review (Q26741859) (← links)
• HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach (Q26780318) (← links)
• Surgical treatment for patients with Krukenberg tumor of stomach origin: clinical outcome and prognostic factors analysis (Q34847458) (← links)
• Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections (Q35831069) (← links)
• Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma. (Q36410392) (← links)
• HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population (Q36849324) (← links)
• Differences in HER2 over-expression between proximal and distal gastric cancers in the Chinese population (Q36897947) (← links)
• Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: A large-scale multicenter study in China (Q37012387) (← links)
• Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies (Q37241496) (← links)
• Associations between serum CA724 and HER2 overexpression among stage II-III resectable gastric cancer patients: an observational study (Q37269090) (← links)
• HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study (Q37308782) (← links)
• HER2-positive gastric cancer (Q37468290) (← links)
• Her2/neu Protein Expression and Oncogene Amplification in Gastric Carcinoma with Clinico-Pathological Correlation in Egyptian Patients. (Q37523508) (← links)
• PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma (Q38752291) (← links)
• HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. (Q39080349) (← links)
• Prognostic importance of RASSF2 expression in patients with gastric cancer who had undergone radical gastrectomy (Q41231684) (← links)
• Role of intravoxel incoherent motion MR imaging in preoperative assessing HER2 status of gastric cancers. (Q41472425) (← links)
• Detection and Significance of Human Epidermal Growth Factor Receptor 2 Expression in Gastric Adenocarcinoma (Q41601800) (← links)
• Expression of human epidermal growth factor receptor 2 in primary and paired parenchymal recurrent and/or metastatic sites of gastric cancer (Q41812451) (← links)
• Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis (Q43479667) (← links)
• Prognostic significance of c-erbB2 overexpression in patients with metastatic gastric cancer (Q44978934) (← links)
• Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis (Q46251162) (← links)
• Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study. (Q47425148) (← links)
• Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer. (Q48379063) (← links)
• HER2 expression in carcinomas of the true cardia (Siewert type II esophagogastric junction carcinoma). (Q51777964) (← links)
• Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer: a meta-analysis of the literature. (Q53134672) (← links)
• Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers. (Q53424338) (← links)
• Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. (Q54218339) (← links)
• Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. (Q54321983) (← links)
• Preferential HER2 expression in liver metastases and EGFR expression in peritoneal metastases in patients with advanced gastric cancer. (Q54326192) (← links)
• Epidemiology and survival outcomes of mucinous adenocarcinomas: A SEER population-based study. (Q54967257) (← links)
• Incorporation of p-53 mutation status and Ki-67 proliferating index in classifying Her2-neu positive gastric adenocarcinoma. (Q55264153) (← links)
• Strategy for treatment of stage IV human epidermal growth factor 2-positive gastric cancer: a case report (Q64112142) (← links)
• Clinicopathological features and endoscopic findings of HER2-positive gastric cancer (Q87944884) (← links)
• A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity (Q88055520) (← links)
• Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India (Q88869075) (← links)
• Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1 (Q90600978) (← links)
• Prognostic significance of Human epidermal growth factor receptor-2 expression in patients with resectable gastric adenocarcinoma (Q91804612) (← links)
• HER2 Oncogene Amplification and Immunohistochemical Profiling in Gastric Adenocarcinoma (Q92070070) (← links)
• Development and Validation of an Easy-to-Implement, Practical Algorithm for the Identification of Molecular Subtypes of Gastric Cancer: Prognostic and Therapeutic Implications (Q92351826) (← links)